American Journal of Multidisciplinary Research & Development (AJMRD)
*Volume 07, Issue 02 (**February - 2025**), PP 73-79*
ISSN: 2360-821X
www.ajmrd.com

Research Paper **Open Access**

The Role of AI in Predicting Cancer Recurrence and Patient Survival Rates

[1]Faroque Md Mohsin, [2]Maherun Nesa, [3]Shekh Mohammad Mostafa, [4]Aditta Das, [5]Dr Zahidul Mostafa, [6]Dr. Rahat Noor, [7]Zeenat Un Nisa, [8]Sibat Asrafy, [9]Sinigdha islam, [10]Mahmudul Mannan

[1]MBBS, MPH, MSS Medical officer Directorate General of Health
https://orcid.org/0000-0003-3432-4559
[2]Registrar MBBS, MS National institute of Burn & Plastic Surgery
https://orcid.org/0000-0002-3299-7939
[3]UHFPO, DGHS Cell-01711209243
https://orcid.org/0000-0002-9089-315
[4]Hebei Medical University Shijiazhuang, CN MBBS
Orchid id -0009-0007-5650-2703
[5]Assistant professor Cardiology Cox's Bazar medical college
https://orcid.org/0000-0002-8318-0929
[6]Consultant radiology & Imaging Chevron Clinical Laboratory -Cox's Bazar,
[7]Clin. Res. Project Coord.-RI NEPHROLOGY, The Hospital for Sick Children, Toronto, ON
https://orcid.org/0000-0003-1308
[8]MBBS Holy Family Red Crescent Medical College and Hospital, Dhaka, Bangladesh Telemedicine Medical Officer
[9]MBBS, MPH
[10]MSc Candidate, Institute of Medical Science (IMS), Temerty Faculty of Medicine, University of Toronto
https://orcid.org/0000-0002-9932-8772

ABSTRACT:- The paper analyzes machine learning algorithms, deep learning models, as well as AI based genomic and imaging analysis, to talk over how AI systems predict cancer recurrence and survival estimates. Three main features which make AI of valuable application to oncology practice includes early warning technology, custom treatment building and real time healthcare record linkage for medical decision. Primary issues in cancer recurrence and patient survival can be predicted by oncologist, where it has a significant impact on treatment strategies and long term outcome. Such prediction methods utilized with statistical means and doctor expertise in cancer care are, however, limited in terms of precision and flexibility. Artificial Intelligence or AI is changing the healthcare operations by freeing up the capability to apply machine learning or deep learning technology to create more precise cancer prognosis predictions. Vanguard prognostic cancer advances will be based on recent developments in explainable AI systems, federated learning, and AI drug discovery technologies. In order to properly set up the ethical criteria for AI implementation as well as augment its positive effects for cancer treatment it will be necessary to initiate the research cooperation with oncologists and policymakers. The research shows that AI technology is transforming oncology and improving results of patients through better prediction systems.

Keywords: Artificial Intelligence (AI), Cancer Recurrence Prediction, Machine Learning in Oncology, Patient Survival Rates, Medical Data Analytics

I. INTRODUCTION

Cancer ranks among the major contributors to worldwide mortality and disease burden since doctors diagnose millions of new cancer cases each year. The primary issue in oncology centers on forecasting cancer recurrence and survival outcomes of patients because these predictions guide treatment selection and ongoing care approaches. The correct recognition of high-risk patients remains essential because cancer recurrence appears after several months up to multiple years following initial therapy. The accuracy of existing prediction strategies dependent on statistical methods, clinical evaluations, and biomarkers experiences limitations when managing different aspects found in individual cancer patient cases. Healthcare professionals now benefit from artificial intelligence (AI) as a strong analytical tool that optimizes studying extensive patient databases to better forecast outcomes. AI implementation in oncology practice enables medical staff to base their choices on richer information and design better treatments while monitoring patients continuously. The paper investigates how artificial intelligence predicts cancer recurrence survival rates and its methods, benefits, and difficulties. The paper examines both current and projected applications of AI technology in cancer care and shows their ability to transform medical settings for the future.

II. OVERVIEW OF CANCER RECURRENCE AND SURVIVAL RATE CHALLENGES

Oncology professionals face the recurrence of cancer as an ongoing issue since it impacts both patient survival potential and duration of survival directly. Cancer recurrence appears when disease cells reappear after remission ends through therapy and may happen within months or years from the beginning of the treatment period. Cancer recurrence takes three primary forms: local recurrence develops where the first cancer originated, and regional recurrence affects the nearest lymph nodes or tissues. However, distant recurrence means the cancer has metastasized to distant body locations. It is essential to predict future incidence of cancer recurrence and survival patterns in order to develop efficient treatment plans and thus, reduce the chances of fatalities and help the patients sustain a better life. However, due to the different biological aspects of the tumor, and different individual patient variations, predicting future cancer recurrence is made difficult. The fact that different patient and tumor characteristics (e.g., the malignant tissue type, the genetic mutation, treatment sensitivity, and the general patient condition) make verified prognostic models difficult to establish. As their main drawback, the existing methods for survival predictions have a tremendous limit. While these predictive models do not reflect the current developments in treatment approaches, targeted therapies, and immunotherapy, almost none depend on data from past times. However, the conventional survival analysis models do not take into account changes in the patient's wellness that occur by virtue of such practices as a change of lifestyle and secondary medical treatments (Susič et al., 2023; Noman et al., 2025).



Furthermore, the availability and quality of data pose significant hurdles. In order to develop precise predictions, datasets containing sufficient patient data with diverse demographics, full treatment response, along with long enough monitoring periods are critical. Among the problems of predictive model development in the healthcare sector is that various providers deal with medical data separately, there are problems with privacy, and the healthcare data between providers is reported inconsistently (Mazaki et al., 2021; Shimada et al., 2022).

III. UNDERSTANDING CANCER RECURRENCE AND SURVIVAL RATE

Definition of Cancer Recurrence and Its Types When cancer patients finish their initial treatment and reach remission, their disease may regrow at the same site or another part of their body. Treatment advancements in oncology do not eliminate the significant challenge of recurrence because such events typically indicate worse disease progression. There are three distinguishable types of cancer recurrence. Treated cancer cells that disappear during remission return to cause disease recurrence when treatment leaves cells behind undetectable to the eye. The cancer spreads to neighboring lymph nodes and surrounding body tissues in the same anatomic region where the tumor originated. The high-risk nature of expanded tumor growth is indicated through this recurrence style. Worldwide studies, including Mazo et al. (2022) and Noman et al. (2025), have proved that distant recurrence along with poor survival rates become associated with the most severe type of cancer return (Mazo et al., 2022; Noman et al., 2025). Doctors require knowledge about the recurrence type when selecting proper treatments and evaluating patient survival forecasts. B. Factors Affecting Cancer Recurrence and Survival Rates Cancer recurrence risk and a patient's survival duration prove challenging to estimate due to multiple influencing factors. These factors include the following: The risk of tumor recurrence directly depends upon three factors: tumor size, tumor stage, and histological subtype during diagnosis. The risk of tumor recurrence grows higher when both tumor grade and stage of diagnosis are advanced (Susič et al., 2023).

The risk of tumor recurrence decreases when patients receive either entire tumor removal surgery or receive responsive chemotherapy, or targeted therapy treatments. The chances of recurrence become higher when patients develop treatment resistance or when treatment outcome is only partial (Shimada et al., 2022). The risk of recurrence increases significantly when patients experience smoking together with obesity and chronic inflammation (Wei et al., 2024). The worst recurrence risks arise approximately five years following the initial diagnosis. Breast and prostate cancer, along with selected other cancers, maintain prolonged recurrence potential beyond ten years of survivorship, according to Dam and Wieder (2024).



IV. AI TECHNIQUES FOR PREDICTING CANCER RECURRENCE AND SURVIVAL

Advantages of AI over statistical models and clinical prediction methods that predict probabilities of cancer recurrence and survival are obtained. Deep learning (CNNs, RNNs, and Transformer Models) has achieved great success as in oncology applications processing complex unorganized data sets (e.g., medical images and time base clinical information). Using algorithms, deep learning, convolutional neural networks (CNNs), recurrent neural networks (RNNs), and transformer models, modern prediction techniques make cancer recurrence, and survival success predictions. CNNs are the main method for image processing, especially so in medical imaging use cases. The analysis of CT scans, along with MRIs and biopsies through CNN,s enables the detection of small tumor appearance or dimension modifications that signal cancer recurrence. The spatial pattern identification abilities of CNNs help medical staff identify early signs of tumor growth and metastasis development (Shimada et al., 2022). Recurrent Neural Networks (RNNs) show exceptional performance when operating on sequential data because they were made specifically for time-dependent outcome prediction. The application of RNNs in cancer prognosis consists of their ability to process patient records containing long-term information, including treatment reactions and health condition transformations. The temporal patterns of patient health, which manifests in disease evolution, become predictable by RNNs due to their capability (Yang et al., 2022). New applications of Transformer models emerged in oncology for analyzing clinical text, genomic sequences, and various types of structured healthcare data. Transformer models stand out from other approaches because they handle enormous datasets including EHRs and genomic information and deliver more dependable survival prognosis results through joint analysis of complex variables (Kaushik et al., 2024).

Tumor Detection benefits from AI-based image analysis through CNNs to achieve top performance when screening cancerous lesions in medical | images, starting with mammograms up to CT MRIs, and PET scans. The algorithms detect tiny tissue structure alterations to identify cancers at their earliest stage,s which go unnoticed by human vision (Akram et al., 2023). Medical detection at an early stage remains vital because it raises survival outcomes and prevents disease return. Medical staff use this method to monitor tumor developments across periods for making appropriate treatment decisions (Feng et al., 2022). Artificial intelligence models review sequential medical images to identify changes in tumor anatomy, enabling them to project the probability of disease relapse. Artificial Intelligence tracks the changes in patient medical scans after therapy to identify precursors of tumor growth or distant spread so healthcare providers can implement prompt therapeutic procedures (Shimada et al., 2022). The process of radiomics allows research teams to extract massive quantitative data from medical images by analyzing their texture features and shape characteristics along with the image intensities. The predictive value of recurrence risk and patient survival can be computed by AI models through deep learning algorithms while analyzing radiomic features (Wei et al., 2024). Personalized cancer treatment planning receives its power from radiomics technology because this method offers biological knowledge about tumors that go past visual identification.



The novel genomic and biomarker analysis powered by artificial intelligence is meant to predict the patient's recurrence and survival from cancer .In addition, AI provides an additional approach to exploring and validating biomarkers based on clinical, genomic, and proteomic data for identifying early detection and recurrence risk biomarkers, such as liquid biopsy and proteomic analysis In this way, AI takes it to a comprehensive level by integrating data from genomics, proteomics and transcriptomics (also known as multiomics data) to get an integrated picture to bring more accuracy in predicting and prognosticating the cancers based on the condition of the patient. Therefore, the treatment process can also include AI models that will adapt to evolving data and deliver dynamic risk assessments along the way that could be used to detect early signs of recurrence to prompt timely interventions. In addition, AI is fundamental to real-time patient monitoring to utilize genetic tests, imaging, and clinical results in real time to risk of recurrence and use in the area of precision medicine. In the end, as AI can crunch and understand massive quantities of detailed data, it can provide the better conjunctured and customized predictions on the recurrence and survival in order to extend the patient outcomes.

V. METHODOLOGY

Using an extensive method, this study evaluates the contribution of the artificial intelligence (AI) to predict cancer recurrence and its survival rate. This research framework is integrated based on a systematic literature review, AI technique analysis based on the data, and case studies on AI applications in oncology. The purpose of that side of the paper is to examine AI hand versions of risk interpretation, analyse the development of imaging, and analyse genomic data to predict cancer outcomes.

With regard to the peer review journal articles, conference proceedings and clinical studies pertaining to AI driven cancer prediction models and Machine learning algorithms or their subset which is deep learning techniques, a review has been done. This research synthesizes public information from relevant datasets containing health records, medical imaging, and genomics for analysis to support the analysis. Case studies and reports from oncological institutions that apply the prediction systems using AI are included. In addition, the study compares traditional statistical models and AI-based techniques in cancer prognosis. the study compares AI-powered models with standard statistical methods, such as Kaplan-Meier survival curves and TNM staging systems, regarding accuracy, efficiency, and real-time adaptation. This evaluation proves AI can process dynamic patient data and enhance predictive precision. Even so, the research focuses on addressing ethical problems in automatic implementation, including data privacy issues in the context of AI models, bias in them, and the demand for interpretability in clinical decision-making.

VI. OBJECTIVES OF THE STUDY

This study attempts to explain the role of artificial intelligence in forecasting cancer recovery and survival rates of a patient via machine learning algorithms, deep learning models, and artificial intelligence based genomic and imaging analysis. According to it, it is meant to assess the role of AI in bestowing advanced oncology services using early warning systems, personalized treatment planning, and real-time healthcare data integration. The study aims to establish a strong argument and achieves it by identifying and using the current and future AI technologies to help enhance accuracy of prognosis, optimization of treatment decisions, and patient outcomes. Sharing final comments underlines the relevance of the ethical perspective and the collaboration of oncologists, data scientists, and policymakers for the responsible AI introduction in cancer care.

VII. RESULTS AND DISCUSSION

These findings show that artificial intelligence (AI) can predict a patient's survival and recurrence better than traditional statistical models. While lots of medical data such as clinical records, imaging scans and genomic sequence are complex and unstructured, AI techniques, especially deep neural algorithms, have presented an amazing capacity for processing such high dimensional data. Results demonstrate the development of prognostic accuracy that far outperforms AI based models due to their capability for dynamic adjustments of predictions made on real time patient data. The main outcome is the increased ability of convolutional neural networks (CNNs) to detect changes in medical imaging with minor tumor pathology. When early tumor growth is recognized in conventional radiology, it is typically too late or CNN-driven image recognition does a far superior job helping prevent or welcomes timely intervention. It is consistent with a few previous studies like Shimada et al. (2022), highlighting the importance of AI-enhanced radiomics to enhance the detection of early stage lung cancer. Recurrent neural networks (RNNs) and transformer models too have strong capabilities of analysing sequential patient data, tracking health status changes, and improving long term survival predictions (Yang et al., 2022).

A comprehensive approach to recurrence risk assessment is based on the integration of multiomics data, genomic, proteomic and transcriptomic data. The results presented by Wei et al. (2024) and Kaushik et al. (2024) confirm the value of AI in kitting huge datasets to uncover recurrence biomarkers and how to better regulate treatment strategies. AI models allow for saving time and eliminating resources that are needed for the study of data. As compared to traditional methods, the AI method based on AI is dynamic and personalized, in contrast to the static datasets used in traditional methods (Dam & Wieder, 2024). AI's adaptability, however, proves incredibly valuable in clinical decision making as they can predict relapse of a disease ahead of conventional means and drto active treatment manipulation.

VIII. CONCLUSION

The study confirms the results of this study; more so, artificial intelligence (AI) significantly improves accuracy and efficiency for cancer recurrence and survival prediction compared to traditional statistical models. Convolutional neural networks (CNNs), recurrent neural networks (RNNs), transformers, and other complex deep learning algorithms are well suited to analyze complex medical data via AI in medicine. Early tumor growth is discovered to be resonant with these models, recurrence risk is predicted, and personalized treatment strategies are outlined with the patient's clinical and genomic information. AI analyzes images for cancer detection early on, detecting soft tumor changes in medical scans that can be caught in time and improve patient outcomes. Furthermore, the multi-omics integration (genomics, proteomics, and transcriptomics) upholds the AI's prediction of biomarkers for biomarker prediction, exceptionally personalized oncology. By adapting forecasts in real-time, real-world patient data can be used to keep the risk assessments up to date and accurate. It will be a while before we have AI come up with cancer prognosis, the scale is not easily achievable, there are issues with data standardization, ethical concerns, and model interpretability. Nonetheless, with additional research and technological progress in overcoming the limitations of AI in oncology, AI will contribute to achieving the true potential of AI in oncology. Looking forward, the main objective is to develop reliable and transparent predictive models that could fit seamlessly into the healthcare workflow, maintaining trustworthiness and transparency for medical practitioners. Overall, AI can facilitate transformation in the field of cancer anticipation, including increased precision of prognostic findings, reduced healthcare expenses, and even facilitated discovery of precision medicine. In the coming years, as AI creates more and more achievements that step closer to antiquity, AI will see more and more changes in oncology, improving cancer treatment survival rates and quality.

REFERENCES:

[1] Adam, N., & Wieder, R. (2024). AI Survival Prediction Modeling: The Importance of Considering Treatments and Changes in Health Status over Time.

[2] Mazo, C., Aura, C., Rahman, A., Gallagher, W. M., & others. (2022). Application of artificial intelligence techniques to predict risk of breast cancer recurrence: a systematic review. Journal of Personalized Medicine. Retrieved from mdpi.com

[3] Susič, D., Syed-Abdul, S., Dovgan, E., & others. (2023). Artificial intelligence-based personalized, predictive survival among colorectal cancer patients. Computer Methods and Programs in Biomedicine. Retrieved from sciencedirect.com

[4] Noman, S. M., Fadel, Y. M., Henedak, M. T., Attia, N. A., & others. (2025). Leveraging survival analysis and machine learning for accurate prediction of breast cancer recurrence and metastasis. Scientific Reports. Retrieved from nature.com

[5] Mazaki, J., Katsumata, K., Ohno, Y., Udo, R., & others. (2021). A novel prediction model for colon cancer recurrence using auto-artificial intelligence. Anticancer Research. Retrieved from iiarjournals.org

[6] Shimada, Y., Kudo, Y., Maehara, S., Amemiya, R., & others. (2022). Radiomics with artificial intelligence for the prediction of early recurrence in patients with clinical stage IA lung cancer. Annals of Surgical Oncology. Retrieved from Springer

[7] Delen, D., Walker, G., & Kadam, A. (2005). Predicting breast cancer survivability: a comparison of three data mining methods. Artificial Intelligence in Medicine. Retrieved from Elsevier

[8] Akcay, M., Etiz, D., & Celik, O. (2020). Machine learning predicts survival and recurrence patterns in gastric cancer cases undergoing radiation therapy and chemotherapy. Advances in Radiation Oncology. Retrieved from ScienceDirect

[9] Javanmard, Z., Shahraki, S. Z., Safari, K., & others. (2025). Artificial intelligence in breast cancer survival prediction: a comprehensive systematic review and meta-analysis. Frontiers in Oncology.

[10] Yang, Y., Xu, L., Sun, L., Zhang, P., & Farid, S. S. (2022). Machine learning application in personalized lung cancer recurrence and survivability prediction. Computational and Structural Biotechnology Journal. Retrieved from ScienceDirect

[11] Fernandez, G., Prastawa, M., Madduri, A. S., Scott, R., & others. (2022). Development and validation of an AI-enabled digital breast cancer assay to predict early-stage breast cancer recurrence within 6 years. Breast Cancer Research. Retrieved from Springer

[12] Kumar, Y., Gupta, S., Singla, R., & Hu, Y. C. (2022). A systematic review of artificial intelligence techniques in cancer prediction and diagnosis. Archives of Computational Methods in Engineering. Retrieved from Springer

[13] Cruz, J. A., & Wishart, D. S. (2006). Applications of machine learning in cancer prediction and prognosis. Cancer Informatics. Retrieved from SAGE Journals

[14] Kaushik, A., Madhuranath, B., Rao, D., & others. (2024). Interpreting breast cancer recurrence prediction models: Exploring feature importance with explainable AI. IEEE Xplore. Retrieved from IEEE

[15] Wei, G. X., Zhou, Y. W., Li, Z. P., & Qiu, M. (2024). Application of artificial intelligence in the diagnosis, treatment, and recurrence prediction of peritoneal carcinomatosis. Heliyon. Retrieved from Cell Press

[16] Jerez-Aragonés, J. M., Gómez-Ruiz, J. A., & others. (2003). A combined neural network and decision trees model for prognosis of breast cancer relapse. Artificial Intelligence in Medicine. Retrieved from Elsevier

[17] Feng, Y., Wang, Z., Cui, R., Xiao, M., Gao, H., Bai, H., & others. (2022). Clinical analysis and artificial intelligence survival prediction of serous ovarian cancer based on preoperative circulating leukocytes. Journal of Ovarian Research. Retrieved from Springer

[18] Janik, A., Torrente, M., Costabello, L., Calvo, V., & others. (2023). Machine learning–assisted recurrence prediction for patients with early-stage non–non-small-cell lung cancer. JCO Clinical Cancer Informatics. Retrieved from ASCO

[19] Palapattu, G. S., Cote, R. J., Sagalowsky, A. I., & others. (2008). Multiple biomarkers improve prediction of bladder cancer recurrence and mortality in patients undergoing cystectomy. Cancer. Retrieved from Wiley

[20] Zuo, D., Yang, L., Jin, Y., Qi, H., Liu, Y., Ren, L. (2023). Machine learning-based models for the prediction of breast cancer recurrence risk. BMC Medical Informatics and Decision Making. Retrieved from Springer

[21] Akram, F., Wolf, J. L., Trandafir, T. E., Dingemans, A. M. C., & others. (2023). Artificial intelligence-based recurrence prediction outperforms classical histopathological methods in pulmonary adenocarcinoma biopsies. Lung Cancer. Retrieved from ScienceDirect

[1]Faroque Md Mohsin,
[1]MBBS, MPH, MSS Medical officer Directorate General of Health
https://orcid.org/0000-0003-3432-4559